Events Archives - Page 47 of 128

1 minute read

Events
News

Zevra Therapeutics Announced Late Saturday, Presentation Of Full Data Set On The Cardiovascular Safety And Pharmacokinetics Of SDX, The Sole API In KP1077, In Healthy Volunteers At Psych Congress 2023

September 10, 10:38 AM

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced a poster presentation featuring study data that underscores the cardiovascular safety profile of

ZVRA

1 minute read

Events
News

Mirati Late Saturday, Announced Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response And Long-Term Overall Survival At 2023 World Conference on Lung Cancer

By Charles Gross

September 10, 10:35 AM

Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and

MRTX

1 minute read

Events
News

Gilead Earlier Announced Phase 2 Evoke-02 Study Of Trodelvy (Sacituzumab Govitecan-hziy) In Combination With Keytruda (Pembrolizumab) Demonstrates Clinical Activity In First-line Metastatic Non-small Cell Lung Cancer

By Charles Gross

September 10, 10:33 AM

Gilead Sciences, Inc. (NASDAQ:GILD) today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in combination with Merck’s

GILD

1 minute read

Events
News

Amgen Presented New Lumakras (Sotorasib) Plus Chemotherapy Data In First-line Kras G12c NASLC At WCLC; Said Data Demonstrated A Confirmed Objective Response Rate Of 65%

By Charles Gross

September 10, 10:30 AM

Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS® (sotorasib) with carboplatin and pemetrexed in adult

AMGN

1 minute read

Events
News

Mineralys Therapeutics Announced Target-htn Successfully Met Its Primary Endpoint; Key Secondary Endpoint Results Demonstrated A Change In Diastolic Aobp Of -7.1 Mmhg With 50mg

By Charles Gross

September 10, 10:27 AM

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated

MLYS

1 minute read

Events
News

Beneficient To Discuss Its Business Model Of Providing Liquidity For Investors In Alternative Assets On Tuesday, September 19, 2023, At 4:30 p.m. EDT

By Happy Mohamed

September 8, 4:18 PM

Beneficient (NASDAQ:BENF) ("Ben" or the "Company"), a technology-enabled platform providing liquidity and related trust and custody services to holders of alternative assets, announced that on

BENF

3 minute read

Novocure Highlights Use Of Tumor Treating Fields Therapy In Treatment Of Non-Small Cell Lung Cancer At 2023 World Conference On Lung Cancer

By Benzinga Newsdesk

September 8, 4:03 PM

Presentations include new post-hoc analysis of data from phase 3 LUNAR trial in metastatic non-small cell lung cancerNovocure (NASDAQ:NVCR) today announced its participation in the upcoming International Association for

NVCR

2 minute read

Is The Cannabis Industry Too Optimistic?

By Joana Scopel

September 7, 5:29 PM

“Everybody thinks it’s just around the corner. It’s going to happen.

NLCP

2 minute read

Apple Unveils iPhone 15 Changes: What’s Coming From Cupertino And Why The Stock Will Cross $200

By Adam Eckert

September 7, 1:36 PM

Apple Inc (NASDAQ: AAPL) is expected to release a handful of new products at its upcoming "Wonderlust" event next week, but all eyes will be on the iPhone 15.

AAPL

1 minute read

BiomX to Present Data From Ongoing Phase 1b/2a Study Evaluating BX004 For The Treatment Of Chronic Pseudomonas aeruginosa Pulmonary Infections In Patients With Cystic Fibrosis At The European Respiratory Society International Congress 2023

By Happy Mohamed

September 7, 9:19 AM

BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the

PHGE